Jasper Therapeutics (NASDAQ:JSPR) Receives Market Outperform Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $70.00 price objective on the stock.

A number of other research firms have also issued reports on JSPR. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $68.00 price target on shares of Jasper Therapeutics in a report on Monday, December 23rd. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Stock Up 8.3 %

NASDAQ JSPR opened at $20.87 on Monday. The business’s 50-day moving average price is $22.05 and its 200 day moving average price is $20.49. The firm has a market cap of $313.07 million, a P/E ratio of -4.40 and a beta of 2.18. Jasper Therapeutics has a 52-week low of $6.61 and a 52-week high of $31.01.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of JSPR. JPMorgan Chase & Co. increased its stake in Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock valued at $308,000 after purchasing an additional 11,567 shares in the last quarter. Barclays PLC boosted its position in shares of Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after buying an additional 12,308 shares in the last quarter. Jane Street Group LLC acquired a new stake in Jasper Therapeutics in the 3rd quarter valued at about $251,000. Wellington Management Group LLP purchased a new position in Jasper Therapeutics during the 3rd quarter valued at about $447,000. Finally, State Street Corp raised its position in Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after acquiring an additional 23,564 shares during the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.